Treatment-duration-wise harm profile of insulin-sodium-glucose co-transporter inhibitor co-treatment in type 1 diabetes mellitus patients

ConclusionOn moderate to long-term treatment (24 –52 weeks) of T1DM patients, insulin-SGLT2i co-treatment was associated with GI risk, and insulin-sotagliflozin co-treatment was associated with DKA and GI risk.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research